On May 27, 2026 Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, reported the close of its seed financing. The close brings total capital raised to $6 million since the company’s founding in 2025. Investors include Unshackled Ventures, 1517 Fund, and Narya.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds will support continued development of the company’s lead program, expansion of its AI discovery engine, and CMC activities.

Reprogram Biosciences is developing a new class of therapeutics based on in situ cell reprogramming, where mRNA-encoded gene combinations, delivered directly into the tumor, activate the immune system by inducing antigen-presenting function in tumor cells. This approach is designed to transform the immunosuppressive tumor microenvironment into a site of active immune priming, with the goal of generating systemic antitumor immune responses.

"Many solid tumors remain difficult to treat despite advances in immunotherapy," said Rustam Esanov, CEO and co-founder of Reprogram Biosciences. "Our approach is differentiated by its reprogramming of the tumor itself into a site of immune activation, rather than relying on exogenous immune cells or broadly acting systemic agents."

"This is a first-in-class approach to a problem that kills 10 million people a year, built by founders who moved from concept to in vivo data in six months with unparalleled capital efficiency," said Colin Greenspon, co-founder and partner at Narya. "That’s the kind of team and science Narya was built to back."

Reprogram identifies and prioritizes therapeutic reprogramming candidates with CellRecodeX, its AI discovery engine. CellRecodeX integrates multiple biological foundation models and is designed to support candidate nomination and pipeline expansion across indications.

(Press release, Reprogram Biosciences, MAY 27, 2026, View Source [SID1234666134])

On May 27, 2026 Genomic Testing Cooperative, a molecular diagnostics company advancing comprehensive cancer profiling through DNA and RNA analysis, reported it will exhibit and present research at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. ASCO (Free ASCO Whitepaper) 2026 will bring together the global oncology community to explore high-impact cancer research, clinical advances, and new technologies shaping the future of cancer care. More than 3,400 abstracts are expected to be presented at this year’s meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

WHAT:
GTC will be available throughout ASCO (Free ASCO Whitepaper) 2026 to connect with media, oncology leaders, industry analysts, financial analysts, pharmaceutical companies, cancer centers, laboratories and potential strategic partners interested in the company’s comprehensive testing platform, cooperative business model and approach to precision cancer diagnostics.

WHEN:
May 29 to June 2, 2026

WHERE:
McCormick Place, Chicago – Booth #17146

GTC PRESENTATIONS AND AFFILIATED POSTERS:

Details for each presentation are available at genomictestingcooperative.com/asco2026/, and the posters will be posted here after ASCO (Free ASCO Whitepaper).

Session: Hematologic Malignancies | Lymphoma and Chronic Lymphocytic Leukemia

Defining APOBEC-like signature in diffuse large B-cell lymphoma and demonstration of distinct transcriptomic profile.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 7075 Poster Board 573

Session: Breast Cancer | Metastatic

Dominant chromosomal abnormalities in breast cancer metastasis to CNS as compared with systemic metastasis demonstrated by liquid biopsy.

Date: Jun 1, 2026 – 1:30-4:30 PM CDT

Abstract: 1035 Poster Board 149

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.

Date: Jun 1, 2026 – 9 AM – 12PM CDT

Abstract: 6538 Poster board 331

Session: Developmental Therapeutics | Molecularly Targeted Agents and Tumor Biology

Comprehensive profiling and clinical utility of CSF-derived cell-free DNA/RNA for evaluation of solid and hematologic malignancies affecting the central nervous system.

Date: May 30, 2026

Abstract: 3066 Poster Board 203

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.

Date: Jun 1, 2026

Abstract: 6545 Poster Board: 338

Session: Hematologic Malignancies | Leukemia, Myelodysplastic Syndromes, and Allotransplant

A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.

Date: Jun 1, 2026

Abstract: 6540 Poster Board: 333

MEDIA AND ANALYST OPPORTUNITIES
Members of the media, industry analysts and financial analysts may schedule meetings with GTC leadership to discuss:

New research being presented at ASCO (Free ASCO Whitepaper) 2026

The role of comprehensive DNA and RNA testing in precision oncology
Liquid biopsy applications, including CSF-based testing for cancers affecting the central nervous system
GTC’s approach to hematologic malignancies, solid tumors and metastatic disease
The company’s cooperative model and opportunities for laboratories, oncology practices and strategic partners
GTC’s growth strategy, including opportunities to expand access to comprehensive molecular testing
WHY GTC MATTERS:
Cancer is complex, and treatment decisions increasingly depend on complete molecular information. GTC’s platform analyzes both DNA and RNA to help identify clinically meaningful biomarkers that more limited testing approaches may miss. GTC approach in RNA sequencing and utilization with artificial intelligence has lead to multiple new tests and discovery of unique biomarkers. For oncologists, pathologists, cancer centers, laboratories and research partners attending ASCO (Free ASCO Whitepaper), GTC offers a differentiated model designed to support comprehensive cancer profiling, clinical interpretation and broader access to precision diagnostics.

WHO:
GTC leaders available for interviews and briefings include:

Maher Albitar, MD, Founder, CEO and Chief Medical Officer
Ahmad Charifa, MD
Adam Zrinsky Albitar, MD
Jennifer Varca, President
Jeff Owen, VP, Marketing and International Sales
Colleen Zirpoli, VP, Sales
To schedule a meeting with GTC at ASCO (Free ASCO Whitepaper) 2026, contact Cara Stewart at [email protected] or +1 949-290-5563; details are available at genomictestingcooperative.com/asco2026.

(Press release, Genomic Testing Cooperative, MAY 27, 2026, View Source [SID1234666087])

On May 27, 2026 Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, reported that management will participate in the following June investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2026 Jefferies Global Healthcare Conference
Date:
Fireside chat:
Place:
Webcast Link:
Wednesday, June 3, 2026
10:30 a.m. ET
Marriott Marquis, New York, NY
Here

Goldman Sachs 47th Annual Global Healthcare Conference
Date:
Place:
Monday, June 8, 2026
Loews Miami Beach, Miami Beach, Fla.

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the respective conference coordinators.

A live audio webcast of the Jefferies Global Healthcare Conference can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of the webcast will be available for 60 days on the Company’s website following the conference.

(Press release, Supernus, MAY 27, 2026, View Source [SID1234666103])

On May 27, 2026 Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medical need, reported that two abstracts featuring (Z)-endoxifen have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held May 29 to June 2, 2026 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Both abstracts highlight the scientific rationale and ongoing clinical development of (Z)-endoxifen in ER-positive breast cancer," said Dr. Steven C. Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa Therapeutics. "Our preclinical data demonstrate that (Z)-endoxifen achieved robust estrogen receptor inhibition across clinically relevant ESR1 mutations associated with endocrine resistance, while the EVANGELINE trial is evaluating its potential in combination with ovarian function suppression in premenopausal women in the neoadjuvant setting. Together, these abstracts underscore our belief that (Z)-endoxifen has the potential to address important unmet needs across multiple treatment settings in ER-positive breast cancer."

Presentation details are as follows:

Session Type: Online Publication
Abstract Title: Effect of (Z)-endoxifen Demonstrates Robust Estrogen Receptor Signaling Inhibition Across Clinically Relevant ESR1 Mutations

Summary: The abstract highlights new preclinical data demonstrating that (Z)-endoxifen delivers robust ER inhibition across clinically relevant estrogen receptor alpha gene (ESR1) mutations. ESR1 mutations are a major mechanism of acquired endocrine resistance in ER-positive breast cancer and remain associated with limited treatment options despite the emergence of next-generation endocrine therapies. These data therefore support the ongoing clinical development of (Z)-endoxifen, as well as its potential as a promising treatment option for breast cancer patients with limited therapeutic alternatives.

Key Data Highlights

(Z)-endoxifen demonstrated robust dose-dependent and statistically significant inhibition of ER signaling across clinically relevant concentrations.
In parental MCF-7 breast cancer cells, ER activity was reduced to 16-26% of control (p < 0.001). In ESR1 wild-type models, studied therapies reduced ER signaling to <5% of control (p < 0.001).
(Z)-endoxifen maintained consistent ER inhibition across key ESR1 mutations (Y537N, Y537S, D538G) (p < 0.01).
Comparator oral Selective Estrogen Receptor Degraders (SERDs), including elacestrant and imlunestrant, showed reduced efficacy in ESR1-mutant settings, particularly in D538G, as compared to (Z)-endoxifen.
The D538G mutation demonstrated the highest resistance, while Y537N remained the most sensitive across treatments.
Session Type: Poster Presentation
Date: June 1, 2026, 1:30 PM-4:30 PM CT
Poster Board Number: 133b
Abstract Title: A Phase 2 Clinical Trial in Progress of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)
Presenters: Dr. Steven C. Quay & Hayley Erickson

Summary: The abstract describes EVANGELINE (NCT05607004), an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg (Z)-endoxifen plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.

Key Highlights

EVANGELINE is evaluating (Z)-endoxifen plus ovarian function suppression (OFS) as a neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.
The primary objective is to determine the proportion of patients with baseline Ki-67 >10% who achieve Ki-67 of 10% or less after 4 weeks of therapy.
A Simon two-stage design is being used to study whether, after four weeks, at least 65% of patients treated achieved a Ki-67 of 10% or less, with 20 patients enrolled in the first stage and, if promising, another 25 patients enrolled in the second stage (cohort A).
A parallel cohort of 20 patients with baseline Ki-67 of 10% or less (cohort B) is enrolled to assess objective response rate at 24 weeks per RECIST v1.1.
Secondary objectives include safety and tolerability, residual cancer burden, and PEPI score; correlative analyses include examining the effect of treatment on select tumor and plasma biomarkers.
A pharmacokinetic run-in phase has been completed and informed selection of (Z)-endoxifen 40 mg daily plus OFS for Phase 2 evaluation. Phase 2 enrollment opened in May 2025.
About ESR1-Mutant Breast Cancer

Mutations in ESR1 commonly arise in patients with advanced ER+ breast cancer following endocrine therapy and are associated with resistance to treatment. These mutations drive ligand-independent ER activation, leading to continued tumor growth despite standard therapies. Effective treatment options for ESR1-mutant disease remain limited.

About EVANGELINE

EVANGELINE (NCT05607004) is an ongoing, multicenter, open-label Phase 2 study evaluating (Z)-endoxifen plus goserelin as a neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer. The study will characterize early antiproliferative activity, clinical response, safety and biologic effects of dual ER and PKCβ1/AKT pathway targeting in this setting.

(Press release, Atossa Therapeutics, MAY 27, 2026, View Source [SID1234666119])

On May 27, 2026 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, reported that orelabrutinib (HIBRUKA) has been approved by the Therapeutic Goods Administration (TGA) in Australia, offering a new treatment option for patients with Mantle Cell Lymphoma (R/R MCL) in the region.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, "The approval of orelabrutinib in Australia marks another important milestone in InnoCare’s global footprint and brings a new treatment option to patients with lymphoma in the region. Beyond oncology, we are also advancing global clinical trials of orelabrutinib in autoimmune diseases."

MCL is a distinct subtype of B-cell non-Hodgkin’s lymphoma (NHL). It is an aggressive and currently incurable disease with rising incidence rate. Patients are often diagnosed at an advanced stage with limited treatment options and poor prognosis.

Orelabrutinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases. With its high target selectivity, it minimizes off-target effects, thereby improving both safety and efficacy.

Orelabrutinib has been approved in Singapore for the treatment of patients with R/R MCL and R/R MZL (marginal zone lymphoma). In China, Orelabrutinib has been approved for the treatment of four lymphoma indications, all of which have been included in China’s National Reimbursement Drug List.

(Press release, InnoCare Pharma, MAY 27, 2026, View Source [SID1234666135])